Sponsor:
Wake Forest University Health Sciences
Code:
NCT06644625
Conditions
Multiple Myeloma
Multiple Myeloma Progression
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Smoldering Multiple Myeloma (SMM)
Plasma Cell Disorders
Eligibility Criteria
Sex: All
Age: 30+
Healthy Volunteers: Accepted
Interventions
Blood draw for the laboratory assessment
Brief summary:
Conditions
Multiple Myeloma
Multiple Myeloma Progression
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Smoldering Multiple Myeloma (SMM)
Plasma Cell Disorders
Study ID
NCT06644625
Start date
Mar 1, 2025
Status verified date
Jul, 2026
Completion date
Jan, 2035
Anticipated
Primary completion date
Jan, 2035
Anticipated
Eligibility Criteria
Sex: All
Age: 30+
Healthy Volunteers: Accepted
Enrollment
1665 participants
Anticipated
Arms
MGUS and Smoldering Multiple Myeloma
Other Plasma Cell Disorders
Interventions
Blood draw for the laboratory assessment
Primary outcome measure
Central contacts
Locations
Atrium Health Levine Cancer
Recruiting
Charlotte, North Carolina, United States, 28204
Contacts
Principal Investigator:
Manisha Bhutani, MD
Sponsor
Wake Forest University Health Sciences
Last update posted
Jul 13, 2026
Last verified
Jul, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Wake Forest University Health Sciences on 2026-07-13.